BBCMF (Lir Life Sciences) Altman Z2-Score: -3.86 (As of Jun. 24, 2026)


BBCMF Lir Life Sciences Corp BBCMF
15 GF Score
Price $0.05
View Full Analysis

What is Lir Life Sciences Altman Z2-Score?

Lir Life Sciences BBCMF -80.00% 15 Altman Z2-Score is -3.86 as of Jun. 24, 2026. GuruFocus rates BBCMF with a GF Score™ of 15/100. Among 1,399 Biotechnology companies, Lir Life Sciences ranks worse than 56.33% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Lir Life Sciences has a Altman Z2-Score of -3.86, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Lir Life Sciences's Altman Z2-Score or its related term are showing as below:

BBCMF' s Altman Z2-Score Range Over the Past 10 Years
Min: -87.45   Med: -31.73   Max: 4.67
Current: -3.79

During the past 2 years, Lir Life Sciences's highest Altman Z2-Score was 4.67. The lowest was -87.45. And the median was -31.73.


Lir Life Sciences  (OTCPK:BBCMF) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Lir Life Sciences Altman Z2-Score Related Terms


Lir Life Sciences Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Lir Life Sciences's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lir Life Sciences Altman Z2-Score Chart

Lir Life Sciences Annual Data
Trend Apr24 Apr25
Altman Z2-Score
0.00 -59.67

Lir Life Sciences Quarterly Data
Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Altman Z2-Score Get a 7-Day Free Trial 0.00 -59.67 -87.45 4.67 -3.79

BBCMF vs VRTX, REGN, ALNY: Altman Z2-Score Comparison

For the Biotechnology subindustry, Lir Life Sciences's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lir Life Sciences Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lir Life Sciences's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Lir Life Sciences's Altman Z2-Score falls into.


BBCMF
15GF Score
Lir Life Sciences Corp BBCMF
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lir Life Sciences Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Lir Life Sciences's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.8432+3.26*-2.585+6.72*-2.2618+1.05*13.5614
=-3.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Jan. 2026:
Total Assets was $0.83 Mil.
Total Current Assets was $0.76 Mil.
Total Current Liabilities was $0.06 Mil.
Retained Earnings was $-2.14 Mil.
Pre-Tax Income was -1.571 + -0.046 + -0.102 + -0.157 = $-1.88 Mil.
Interest Expense was 0 + -0.001 + 0 + 0 = $-0.00 Mil.
Total Liabilities was $0.06 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.756 - 0.057)/0.829
=0.8432

X2=Retained Earnings/Total Assets
=-2.143/0.829
=-2.585

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-1.876 - -0.001)/0.829
=-2.2618

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(0.773 - 0)/0.057
=13.5614

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Lir Life Sciences has a Altman Z2-Score of -3.86 indicating it is in Distress Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of -3.86 mean?
Lir Life Sciences (BBCMF) has a Altman Z2-Score of -3.86 as of Jun. 24, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Lir Life Sciences and its competitors. According to the industry distribution chart, Lir Life Sciences ranks #788 out of 1399 companies in the Biotechnology industry, placing it in the top 56.3%.
Is Lir Life Sciences' Altman Z2-Score too high?
Lir Life Sciences' current Altman Z2-Score is -3.86. Based on the distribution chart, Lir Life Sciences ranks #788 out of 1399 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #788 out of 1399 companies for Altman Z2-Score. This places Lir Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Lir Life Sciences and its competitors. Lir Life Sciences's current Altman Z2-Score is -3.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current Altman Z2-Score of -3.86. The current Altman Z2-Score is -3.86. Lir Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current Altman Z2-Score is -3.86 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lir Life Sciences Business Description

Other Exchanges N790:GermanySKNY:Canada
Address 505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score

Get the complete analysis for BBCMF

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.05
Price